This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics' Trevyent NDA for PAH Accepted by FDA
by Zacks Equity Research
United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%
by Zacks Equity Research
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
United Therapeutics In-Licenses Rights to IPF Candidate
by Zacks Equity Research
United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.
Implied Volatility Surging for MannKind (MNKD) Stock Options
by Zacks Equity Research
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
MannKind Stock Up on Licensing Deal With United Therapeutics
by Zacks Equity Research
MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.
Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars
by Zacks Equity Research
Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.
Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?
by Zacks Equity Research
Investors in MannKind (MNKD) need to pay close attention to the stock based on moves in the options market lately.
MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and -18.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for MannKind Corporation (MNKD) Stock Options
by Zacks Equity Research
Investors in MannKind (MNKD) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in MannKind (MNKD) Stock?
by Zacks Equity Research
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
MannKind (MNKD) Enters Oversold Territory
by Zacks Equity Research
MannKind Corporation (MNKD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?
by Zacks Equity Research
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in MannKind (MNKD) Stock
by Zacks Equity Research
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
Do Options Traders Know Something About MannKind Corp (MNKD) Stock We Don't?
by Zacks Equity Research
Surging implied volatility makes MannKind Corp (MNKD) Stock lucrative to the option traders.
Implied Volatility Surging for MannKind (MNKD) Stock Options
by Zacks Equity Research
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in MannKind (MNKD) Stock
by Zacks Equity Research
Investors in MannKind (MNKD) need to pay close attention to the stock based on moves in the options market lately.
MannKind (MNKD) in Focus: Stock Moves 7.8% Higher
by Zacks Equity Research
MannKind (MNKD) shares rose nearly 8% in the last trading session, amid huge volumes.
Do Options Traders Know Something About MannKind (MNKD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in MannKind Corporation (MNKD) Stock
by Zacks Equity Research
MannKind Corporation (MNKD) needs Investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in MannKind (MNKD) Stock
by Zacks Equity Research
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in MannKind (MNKD) Stock?
by Zacks Equity Research
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
MannKind Corporation (MNKD) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
MannKind Corporation (MNKD) was a big mover last session, as the company saw its shares rise over 7% on the day amid huge volumes.